Short‐ and long‐term impact of neutropenia within the first year after kidney transplantation

The aim of this retrospective single‐center study was to investigate the short‐ and long‐term impact of neutropenia occurring within the first year after kidney transplantation, with a special emphasis on different neutropenia grades. In this unselected cohort, 225/721 patients (31%) developed 357 neutropenic episodes within the first year post‐transplant. Based on the nadir neutrophil count, patients were grouped as neutropenia grade 2 (<1.5–1.0*10(9)/l; n = 105), grade 3 (<1.0–0.5*10(9)/l; n = 65), and grade 4 (<0.5*10(9)/l; n = 55). Most neutropenia episodes were presumably drug‐related (71%) and managed by reduction/discontinuation of potentially responsible drugs (mycophenolic acid [MPA] 51%, valganciclovir 25%, trimethoprim/sulfamethoxazole 19%). Steroids were added/increased as replacement for reduced/discontinued MPA. Granulocyte colony‐stimulating factor was only used in 2/357 neutropenia episodes (0.6%). One‐year incidence of (sub)clinical rejection, one‐year mortality, and long‐term patient and graft survival were not different among patients without neutropenia and neutropenia grade 2/3/4. However, the incidence of infections was about 3‐times higher during neutropenia grade 3 and 4, but not increased during grade 2. In conclusion, neutropenia within the first year after kidney transplantation represents no increased risk for rejection and has no negative impact on long‐term patient and graft survival. Adding/increasing steroids as replacement for reduced/discontinued MPA might supplement management of neutropenia.